Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer

British Journal of Pharmacology

Volumn 121, Issue 4, 1997, Pages 743-750

  Souness, John E ^a,b   Houghton, Clare ^a   Sardar, Nughat ^a   Withnall, Michael T ^a,c  

^a Dagenham Research Center   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Biochemical Society   (United Kingdom)

Author keywords

Cyclic AMP phosphodiesterase; DNA synthesis; Interleukin 2; Murine splenocytes; Rolipram; RP 73401; Staphylococcal enterotoxin A

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; CYCLOSPORIN A; DEXAMETHASONE; IBUDILAST; INTERLEUKIN 2; MITOGENIC AGENT; NEUTRALIZING ANTIBODY; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PICLAMILAST; ROLIPRAM; SIGUAZODAN; STAPHYLOCOCCUS ENTEROTOXIN A; TREQUINSIN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN; CONTROLLED STUDY; CYTOSOL; DNA SYNTHESIS; DRUG POTENCY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; BENZAMIDES; DNA; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PYRIDINES; SPLEEN;

EID: 0030999319     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701200     Document Type: Article

References (42)

1. 2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2R gene expression at multiple levels. J. Immunol., 148, 2845-2852.
2. ASHTON, M., COOK, D.C., FENTON, G., KARLSSON, J.-A., PALFREYMAN, M.N., RAEBURN, D., RATCLIFFE, A.J., SOUNESS, J.E., THURAIRATNAM, S. & VICKER, N. (1994). Selective type IV phosphodiesterase inhibitors as anti-asthmatic agents. The synthesis and biological activities of 3-cyclopentyloxy-4-methoxybenzamides and analogues. J. Med. Chem., 37, 1696-1703.
3. AVERILL, L.E., STEIN, R.L. & KAMMER, G.M. (1988). Control of human T-lymphocyte interleukin-2 production by a cyclic AMP-dependent pathway. Cell. Immunol., 115, 88-99.
4. BARNETTE, M.S., GROUS, M., CIESLINSKI, L.B., BURMAN, M., CHRISTENSEN, S.B. & TORPHY, T.J. (1995a). Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: Correlation between function and interaction with a high-affinity rolipram binding site. J. Pharmacol. Exp. Ther., 273, 1396-1402.
5. 3H] rolipram binding. Biochem. Pharmacol., 51, 949-956.
6. BARNETTE, M.S., TORPHY, T.J. & CHRISTENSEN, S.B. (1995b). Therapeutic phosphodiesterase IV inhibitors and their selection. WO Patent, 00139. Chem. Abstr. 122: 205-217.
7. BEAVO, J.A. & REIFSNYDER, D.H. (1990). Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sci., 11, 150-155.
8. BOLGER, G. (1994). Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: A diverse family of regulatory enzymes. Cell. Signalling, 6, 851-859.
9. CHRISTENSEN, S.B., DEWOLF, Jr. W.E., RYAN, M.D. & TORPHY, T.J. (1996). Molecular aspects of inhibitor interaction with PDE4. In Handbook of Immunopharmacology: Phosphodiesterase Inhibitors, ed. Dent, G., Rabe, K. & Schudt, C. pp. 185-207. London: Academic Press.
10. DE BRITO, F.B., SOUNESS, J.E. & WARNE, P.J. (1997). Type 4 phosphodiesterase inhibitors and their potential in the treatment of inflammatory disease. Emerging Drugs, 2, (in press).
11. DUPLANTIER, A.J., BIGGERS, M.S., CHAMBERS, R.J., CHENG, J.B., COOPER, K., DAMON, D.B., EGGLER, J.F., KRAUS, K.G., MARFAT, A., MASAMUNE, H., PILLAR, J.S., SHIRLEY, J.T., UMLAND, J.P. & WATSON, J.W. (1996). Biarylcarboxylic acids and -amides: Inhibition of phosphodiesterase type IV versus [3H] rolipram binding activity and their relationship to emetic behaviour in the ferret. J. Med. Chem., 39, 120-125.
12. FISCHER, H., DOHLSTEN, M., LINDVALL, M., SJORGREN, H.-O. & CARLSSON, R. (1989). Binding of staphylococcal enterotoxin A to HLA-DR on B cell lines. J. Immunol., 142, 3151-3157.
13. FRASER, J.D. (1989). High-affinity binding of staphylococcal enterotoxins A and B to HLA-DR. Nature, 339, 221-223.
14. GENAIN, C.P., ROBERTS, T., DAVIS, R.L., NGUYEN, M.-H., UCCELLI, A., FAULDS, D., LI, Y., HEDGPETH, J. & HAUSER, S.L. (1995). Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. U.S.A., 92, 3601-3605.
15. + T-lymphocytes: role in regulating proliferation and biosynthesis of interleukin-2. Br. J. Pharmacol., 118, 1945-1958.
16. GIRI, J.G., ANDERSON, D.M., KUMAKI, S., PARK, L.S., GRANSTEIN, K.H. & COSMAN, D. (1995). IL-15, a novel T-cell growth factor that shares activities and receptor components with IL-2. J. Leukocyte Biol., 57, 763-766.
17. HARRIS, A.L., CONNELL, M.J., FERGUSON, E.W., WALLACE, A.M., GORDON, R.J., PAGANI, E.D. & SILVER, P.J. (1989). Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilatation in the guinea-pig. J. Pharmacol. Exp. Ther., 251, 199-206.
18. HUSTON, E., POOLEY, L., JULIEN, P., SCOTLAND, G., MCPHEE, I., SULLIVAN, M., BOLGER, G. & HOUSLAY, M. (1997). The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species which exhibit distinct kinetics of inhibition by the anti-depressant rolipram. J. Biol. Chem., 271, 31334-31344.
19. JACOBITZ, S., MCLAUGHLIN, M.M., LIVI, G.P., BURMAN, M. & TORPHY, T.J. (1996). Mapping the functional domains of human recombinant phosphodiesterase 4A: Structural requirements for catalytic activity and rolipram binding. Mol. Pharmacol., 50, 891-899.
20. 3H] R-(-)-rolipram binding by selective inhibitors. Biochem. J., 318, 425-436.
21. LEWIS, G.M., CACCESE, R.G., HEASLIP, R.L. & BANSBACH, C.C. (1993). Effects of rolipram and CI-930 on IL-2 mRNA transcription in human Jurkat cells. Agents Actions, 39, C89 -C92.
22. MCLAUGHLIN, M.M., CIESLINSKI, L.B., BURMAN, M., TORPHY, T.J. & LIVI, G.P. (1993). A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterisation of recombinant protein, and tissue distribution of mRNA. J. Biol. Chem., 268, 6470-6476.
23. PALFREYMAN, M.N. & SOUNESS, J.E. (1996). Phosphodiesterase type IV inhibitors. Prog. Med. Chem., 33, 1-52.
24. PRABHAKAR, U., LIPSHUTZ, D., O'LEARY BARTUS, J., SLIVJAK, M.J., SMITH III, E.F., LEE, J.C. & ESSER, K.M. (1994). Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int. J. Immunopharmacol., 16, 805-816.
25. ROBICSEK, S.A., BLANCHARD, D.K., DJEU, J.Y., KRZANOWSKI, J.J., SZENTIVANYI, A. & POLSON, J.B. (1991). Multiple high-affinity cyclic AMP phosphodiesterases in human T-lymphocytes. Biochem. Pharmacol., 42, 869-877.
26. SCHADE, F.U. & SCHUDT, C. (1993). The specific type III and IV phosphodiesterase inhibitor zardavarine suppresses formation of tumor necrosis factor by macrophages. Eur. J. Pharmacol., 230, 9-14.
27. SCHMIECHEN, R., SCHNEIDE, H.H. & WACHTEL, H. (1990). Close correlation between behavioral response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase. Psychopharmacology, 102, 17-20.
28. SCHNEIDER, H.H., SCHMIECHEN, R., BREZINSKI, M. & SEIDLER, J. (1986). Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur. J. Pharmacol., 127, 105-115.
29. SEKUT, L., YARNALL, D., STIMPSON, S.A., NOEL, L.S., BATEMANFITE, R. CLARK, R.L., BRACKEEN, M.F., MENIUS, J.A. & CONNOLLY, K.M. (1995). Anti-inflammatory activity of phosphodiesterase (PDE) IV inhibitors in acute and chronic models of inflammation. Clin. Exp. Immunol., 100, 126-132.
30. SEMMLER, J., WACHTEL, H. & ENDRES, S. (1993). The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int. J. Immunopharmacol., 15, 409-413.
31. SETTE, C., VICINI, E. & CONTI, M. (1994). The rat PDE3/IVd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase. J. Biol. Chem., 269, 18271-18274.
32. SOMMER, N., LOSCHMANN, P.-A., NORTHOFF, G.H., WELLER, M., STEINBRECHER, A., STEINBACH, J.P., LICHTENFELS, R., MEYERMANN, R., RIETHMULLER, A., FONTANA, A., DICHGANS, J. & MARTIN, R. (1995). The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med., 1, 244-248.
33. SOUNESS, J.E., CARTER, C.M., DIOCEE, B.K., HASSALL, G.A., WOOD, L.J. & TURNER, N.C. (1991). Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation. Biochem. Pharmacol., 42, 937-945.
34. SOUNESS, J.E., GRIFFIN, M., MASLEN, C., EBSWORTH, K., SCOTT, L.C., POLLOCK, K., PALFREYMAN, M.N. & KARLSSON, J.-A. (1996). Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFα generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br. J. Pharmacol., 118, 649-658.
35. SOUNESS, J.E., MASLEN, C., WEBBER, S., FOSTER, M., RAEBURN, D., PALFREYMAN, M.N., ASHTON, M.J. & KARLSSON, J.-A. (1995). Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram. Br. J. Pharmacol., 114, 39-46.
36. SOUNESS, J.E. & RAO, S. (1997). A proposal for pharmacologically distinct conformers of PDE4. Cell. Signalling, 8, (in press).
37. SOUNESS, J.E. & SCOTT, L.C. (1993). Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase. Biochem. J., 291, 389-395.
38. THEZE, J., ALZARI, P.M. & BERTOGLIO, J. (1996). Interleukin 2 and its receptors: recent advances and new immunological functions. Immunol. Today, 17, 481-486.
39. THOMPSON, W.J., TERASAKI, W., EPSTEIN, P.M. & STRADA, S.J. (1979). Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv. Cyclic Nucleotide Res., 10, 69-92.
40. TORPHY, T.J., STADEL, J.M., BURMAN, M., CIESLINSKI, L.B., MCLAUGHLIN, M.M., WHITE, J.R. & LIVI, G.P. (1992). Coexpression of human cAMP-specific phosphodiesterase activity and high-affinity rolipram binding in yeast. J. Biol. Chem., 267, 1798-1804.
41. 2+ concentrations in human lymphocytes. Br. J. Pharmacol., 103, 1288-1294.
42. WILLIAMS, R.O., GHRAYEB, J., FELDMAN, M. & MAINI, R.N. (1995). Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology, 84, 433-439.